Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market (Table of Contents)

Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market


February 10, 2011
100 Pages - SKU: XGBR6130342
License type:
Online Download      US $3,500.00
Global Site License      US $10,500.00
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Targeted Therapeutics: Introduction
2.1 GBI Research Guidance
3 Targeted Therapeutics: Overview
3.1 Introduction
3.2 Targeted Therapy is the Need of the Hour
3.2.1 High Side Effects and Toxic Effects of Conventional Therapy
3.2.2 Variable Efficacy Rate of Conventional Drugs at the Affected Site
3.2.3 Resistance Developed to Conventional Drugs Used to Treat Infections
3.3 Targeted Therapeutics Market Drivers and Restraints
3.3.1 Targeted Therapeutics Market Drivers
3.3.2 Targeted Therapeutics Market Restraints
4 Targeted Therapeutics: Major Types of Targeted Therapeutics
4.1 Small Molecules
4.1.1 Overview
4.2 Innovative Small Molecule Therapeutics Market Drivers and Restraints
4.2.1 Small Molecule Therapeutics Market Drivers
4.2.2 Innovative Small Molecule Therapeutics Market Restraints
4.2.3 Profiles of Key Pipeline Molecules
4.3 Proteins/Peptide Drugs
4.3.1 Overview
4.4 Proteins/Peptide Drugs Therapeutics Market Drivers and Restraints
4.4.1 Peptides/Protein Drug Therapeutics Market Drivers
4.4.2 Peptides/Protein Drug Therapeutics Market Restraints
4.4.3 Profiles of Key Pipeline Molecules
4.5 Monoclonal Antibodies (MAbs) and Antibody Like Structures
4.5.1 Overview
4.6 Monoclonal Antibody Therapeutics, Market Drivers and Restraints
4.6.1 Monoclonal Antibody Therapeutics Market Drivers
4.6.2 Global Monoclonal Antibody Market Restraints
4.6.3 Profiles of Key Pipeline Molecules (MAb)
4.7 RNA Interference
4.7.1 Overview
4.8 RNA Interference Therapeutics Market Drivers and Restraints
4.8.1 RNA Interference Therapeutics Market Drivers
4.8.2 RNA Interference Therapeutics Market Restraints
4.8.3 Profiles of Key Pipeline Molecules (RNA)
4.9 Stem Cell Therapies
4.9.1 Overview
4.10 Stem Cell Therapeutics Market Drivers and Restraints
4.10.1 Stem Cell Therapeutics Market Drivers
4.10.2 Stem Cell Therapeutics Market Restraints
4.10.3 Profile of Key Late Stage Therapies
4.11 Gene Therapy
4.11.1 Overview
4.12 Gene Therapy Market Drivers and Restraints
4.12.1 Gene Therapy Market Drivers
4.12.2 Gene Therapy Market Restraints
4.12.3 Key Pipeline Candidates
5 Targeted Therapeutics: Regulatory Landscape
5.1 The US Regulatory Landscape Scenario
5.1.1 National Institute for Health (NIH)
5.1.2 FDA
5.2 EU Regulatory Landscape Scenario
5.2.1 Committee for Advanced Therapies (CAT)
6 Targeted Therapeutics: Competitive Landscape
6.1 Antisoma
6.1.1 Overview
6.1.2 Key Deals
6.2 AVI BioPharma
6.2.1 Overview
6.2.2 Key Deals
6.3 Biogen
6.3.1 Overview
6.3.2 Key Deals
6.4 Cephalon
6.4.1 Overview
6.4.2 Key Deals
6.5 Eli Lilly
6.5.1 Overview
6.5.2 Key Deals
6.6 Forest Laboratories
6.6.1 Overview
6.6.2 Key Deals
6.7 Genmab
6.7.1 Overview
6.7.2 Key Deals
6.8 Gilead Sciences
6.8.1 Overview
6.8.2 Key Deals
6.9 Hoffmann La- Roche (Genentech)
6.9.1 Overview
6.9.2 Key Deals
6.10 Isis Pharmaceuticals
6.10.1 Overview
6.10.2 Key Deals
6.11 Johnson and Johnson (J&J)
6.11.1 Overview
6.11.2 Key Deals
6.12 Mesoblast Limited
6.12.1 Overview
6.12.2 Key Deals
6.13 Pfizer
6.13.1 Overview
6.13.2 Key Deals
6.14 UCB
6.14.1 Overview
6.14.2 Key Deals
7 Targeted Therapeutics Market - Appendix
7.1 Market Definitions
7.2 List of Abbreviations
7.3 Research Methodology
7.3.1 Coverage
7.3.2 Secondary Research
7.3.3 Primary Research
7.3.4 Expert Panel Validation
7.4 Contact Us
7.5 Disclaimer
7.6 Sources
1.1 List of Tables
Table 1: Key Small Molecule Drugs Used For Targeted Therapeutics and Their Indications, 2010
Table 2: Key Small Molecule Drugs, Global, Sales Value ($m), 2007-2009
Table 3: Key Protein/Peptide Drugs, Generic Names and Approved Indications, 2010
Table 4: Key Protein/Peptide Drugs, Global, Sales Value ($m), 2007-2009
Table 5: Key Monoclonal Antibodies (MAbs) and Their Approved Indications
Table 6: Key Monoclonal Antibodies, Global, Sales Value ($m), 2007-2009
Table 7: List of Key EMA Directives and Guidelines for GTMPs
1.2 List of Figures
Figure 1: Targeted Therapeutics, Global, Market Drivers and Restraints, 2010
Figure 2: Key Small Molecule Drugs, Global Sales ($m), 2007- 2009
Figure 3: Small Molecule Therapeutics, Global, Market Drivers and Restraints, 2010
Figure 4: Key Protein/Peptide Drugs, Global Sales ($m), 2007-2009
Figure 5: Protein/Peptide Drug Therapeutics, Global, Market Drivers and Restraints, 2010
Figure 6: Key Monoclonal Antibodies, Global, Sales Value ($m), 2007-2009
Figure 7: Monoclonal Antibody Therapeutics, Global, Market Drivers and Restraints, 2010
Figure 8: RNA Interference Therapeutics, Global, Market Drivers and Restraints, 2010
Figure 9: Types Of Stem Cells, Depending Upon Their Potential
Figure 10: Stem Cell Therapeutics, Global, Market Drivers and Restraints, 2010
Figure 11: Gene Therapy, Global, Market Drivers and Restraints, 2010
Figure 12: Definition of Advanced Therapy Medicinal Products by the European Commission